Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Clinical Trials01:16

Clinical Trials

10.4K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.4K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.3K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.3K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

1.5K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.5K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Trial and Error and Algorithm01:12

Trial and Error and Algorithm

407
A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...
407

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.

The American journal of cardiology·2013
Same author

Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.

Circulation·2013
Same author

Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry.

Clinical cardiology·2013
Same author

Synthesizing lessons learned from get with the guidelines: the value of disease-based registries in improving quality and outcomes.

Circulation·2013
Same author

Lipoprotein(a) for risk assessment in patients with established coronary artery disease.

Journal of the American College of Cardiology·2013
Same author

Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis.

JAMA·2013

相关实验视频

Updated: Jan 31, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

药物代价券对P2Y12抑制剂使用和心肌梗塞患者的主要不良心血管事件的影响:ARTEMIS随机临床试验

Tracy Y Wang1, Lisa A Kaltenbach1, Christopher P Cannon2

  • 1Duke Clinical Research Institute, Durham, North Carolina.

JAMA
|January 9, 2019
PubMed
概括

消除P2Y12抑制剂的共同支付障碍增加了心肌梗塞 (MI) 患者的药物持续性. 然而,这种干预措施并没有在一年内显著减少主要心血管不良事件 (MACE).

更多相关视频

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.7K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.7K

相关实验视频

Last Updated: Jan 31, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.7K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.7K

科学领域:

  • 心血管医学
  • 临床试验
  • 健康经济学

背景情况:

  • 许多患者在心肌梗塞 (MI) 后过早停止P2Y12抑制剂治疗,这与指导方针相反.
  • 高效的P2Y12抑制剂未得到充分利用,成本经常被列为主要原因.
  • 了解财务障碍对药物坚持的影响对于改善心血管结果至关重要.

研究的目的:

  • 评估是否消除P2Y12抑制剂的共同支付成本可以改善患者对治疗的坚持.
  • 评估降低财务负担对心血管重大不良事件 (MACE) 的影响.

主要方法:

  • 一个集群随机临床试验,涉及301家医院和超过11000名急性心脏病患者.
  • 干预组医院提供了一年P2Y12抑制剂 (克洛皮多格雷尔或提卡格雷尔) 的共同支付券.
  • 对照组接受了通常的护理,没有研究提供的凭证;结果在解诊后的一年后进行评估.

主要成果:

  • 与通常治疗组 (83. 8%) 相比,干预组的P2Y12抑制剂持续性显著增加,绝对增加为3. 3%.
  • 尽管持续性有所改善,但两组在MACE (死亡,复发性心脏病或中风) 一年后的综合结果上没有显著差异.
  • 约有72%的干预组患者使用了共同支付券.

结论:

  • 提供P2Y12抑制剂的共同支付券有效地增加了心脏病发作后患者的药物持续性.
  • 仅靠经济激励可能不足以减少重大心血管不良事件,这表明其他因素也会影响MACE.
  • 解决药物成本障碍对于遵守是很重要的,但需要采取多方面的方法来影响临床事件率.